Loading
Life sciences · Journal article
Current Issues in Molecular Biology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer is the most common malignancy in women and a major cause of cancer-related deaths, yet effective biomarkers that predict progression and guide therapy remain limited. This study explored the role of Transcription Factor 19 (TCF19) in breast cancer using public multi-omics datasets and in vitro functional assays. We first assessed TCF19 expression and its clinical associations and analysed co-expressed genes through network construction and pathway enrichment. We then evaluated immune cell infiltration, and examined proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in breast cancer cell lines following TCF19 knockdown. A prognostic nomogram integrating TCF19 with clinical variables was also constructed. TCF19 was significantly overexpressed in breast cancer at both mRNA and protein levels. High TCF19 expression correlated with aggressive features, including larger tumour size, HER2 positivity, hormone receptor negativity, and high MKI67 expression, and was associated with poorer overall, disease-specific, and progression-free survival in univariate analyses, with the strongest association observed in HER2-positive patients. TCF19-related genes were mainly involved in cell-cycle regulation and chromosome segregation, and elevated TCF19 was associated with increased immunosuppressive cell infiltration and reduced CD8+ T cells and natural killer (NK) cells. In vitro, TCF19 silencing reduced CDK1 levels, impaired proliferation, migration, and invasion, and reversed EMT. Although the TCF19-containing nomogram showed encouraging internal calibration (C-index = 0.762), TCF19 did not remain an independent prognostic factor after adjustment for clinical confounders. Overall, our findings indicate that TCF19 is a candidate prognostic biomarker and potential therapeutic target in breast cancer that warrants independent clinical and in vivo validation.